We are live on ! Find out more
MRNS

Marinus Pharmaceuticals, Inc
MRNS

Delisted

MRNS was delisted on the 10th of February, 2025.

Back to rankings

65 hedge funds and large institutions have $210M invested in Marinus Pharmaceuticals, Inc in 2017 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 15 increasing their positions, 13 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

450% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 6

78% more capital invested

Capital invested by funds: $118M → $210M (+$92.3M)

73% more call options, than puts

Call options by funds: $2.25M | Put options by funds: $1.3M

71% more funds holding

Funds holding: 38 → 65 (+27)

15% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 13

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
65
Holders Change
+27
Holders Change %
+71.05%
% of All Funds
1.47%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
33
Increased
15
Reduced
13
Closed
6
Calls
$2.25M
Puts
$1.3M
Net Calls
+$953K
Net Calls Change
+$953K

Top Buyers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
+$7.34M
2
AC
Ascend Capital
California
+$6.82M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$6.74M
4
Citadel Advisors
Citadel Advisors
Florida
+$6.54M
5
6CM
683 Capital Management
New York
+$3.71M

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$21.3M
2
DM
Deerfield Management
New York
-$7.95M
3
PA
Perceptive Advisors
New York
-$3.67M
4
GPCM
Granite Point Capital Management
Massachusetts
-$2.74M
5
BIM
Bogle Investment Management
Massachusetts
-$2.25M
Name Holding Trade Value Shares
Change 		Change in
Stake
OAM
26
Oxford Asset Management
United Kingdom
$1.12M +$890K +33,014 New
ARTA
27
A.R.T. Advisors
New York
$1.03M +$855K +31,738 New
HCMT
28
Highland Capital Management (Texas)
Texas
$955K +$788K +29,256 New
EGI
29
EAM Global Investors
California
$905K +$748K +27,742 New
IHM
30
Iguana Healthcare Management
New York
$816K -$505K -18,750 -43%
Susquehanna International Group
31
Susquehanna International Group
Pennsylvania
$556K -$118K -4,364 -20%
Northern Trust
32
Northern Trust
Illinois
$412K +$32.3K +1,198 +10%
EMG
33
Ellington Management Group
Connecticut
$330K -$31K -1,150 -10%
VEA
34
Virtus ETF Advisers
New York
$308K +$255K +9,451 New
VFA
35
Virtus Fund Advisers
Connecticut
$308K +$255K +9,451 New
Goldman Sachs
36
Goldman Sachs
New York
$305K +$252K +9,336 New
State Street
37
State Street
Massachusetts
$279K -$39.2K -1,456 -15%
Bank of New York Mellon
38
Bank of New York Mellon
New York
$271K +$76.6K +2,841 +52%
TI
39
Trexquant Investment
Connecticut
$230K +$190K +7,059 New
Wells Fargo
40
Wells Fargo
California
$225K +$185K +6,881 New
FPF
41
FNY Partners Fund
New York
$183K +$152K +5,625 New
MWNA
42
Marshall Wace North America
New York
$181K -$1.65M -61,241 -92%
ProShare Advisors
43
ProShare Advisors
Maryland
$178K +$147K +5,446 New
GCP
44
GSA Capital Partners
United Kingdom
$167K +$138K +5,125 New
Squarepoint
45
Squarepoint
New York
$158K +$131K +4,845 New
CC
46
Caxton Corporation
New Jersey
$152K +$16.5K +611 +15%
DTL
47
Dynamic Technology Lab
Singapore
$146K +$121K +4,491 New
TD Asset Management
48
TD Asset Management
Ontario, Canada
$137K +$113K +4,200 New
Dimensional Fund Advisors
49
Dimensional Fund Advisors
Texas
$123K – – –
MIM
50
Monashee Investment Management
Massachusetts
$94K – – –
1
2
3

MRNS Hedge Fund Activity: Q4 2017 in Review

65 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q4 2017, worth a combined $210M — up 78% from $118M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new MRNS positions and 6 closed out — a net gain of 27 holders — while 15 added to existing stakes and 13 trimmed.

The largest buyer was Jennison Associates, adding an estimated $7.34M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $21.3M sold.

  • 65 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q4 2017, up from 38 in Q3 2017.
  • Funds reported $210M of Marinus Pharmaceuticals, Inc stock for Q4 2017, up 78% quarter-over-quarter.
  • 33 funds opened new Marinus Pharmaceuticals, Inc positions in Q4 2017 and 6 closed out, a net change of +27 holders.
  • The largest Marinus Pharmaceuticals, Inc buyer in Q4 2017 was Jennison Associates, an estimated $7.34M added.
  • The largest Marinus Pharmaceuticals, Inc seller in Q4 2017 was EcoR1 Capital, an estimated $21.3M sold.

Based on aggregated 13F filings for Q4 2017.